Dexmedetomidine Premedication for Minor Gynecologic Surgery

Publisher Website
Google Scholar
Abstract
The effects of four different doses (0.167, 0.33, 0.67, and 1.0 .mu.g/kg) of dexmedetomidine, a novel .alpha.2-adrenoceptor agonist, on anesthetic requirements, hemodynamics, and plasma catecholamine levels were investigated in a single-blind fashion in 20 healthy (ASA physical status I) women scheduled for uterine dilatation and curettage. The drug was administered intravenously 15 min before anesthesia induction with thiopental. Nitrous oxide/oxygen (70%/30%) was used for maintenance. Dexmedetomidine was well tolerated, and no serious drug-related subjective side effects or adverse events were observed. The most prominent subjective effects were tiredness and decreased salivation. The total amount of thiopental needed to perform uterine dilatation and curretage was decreased dose-dependently from 400 .+-. 166 mg (mean .+-. SD) after 0.167 .mu.g/kg of dexmedetomidine to 180 .+-. 65 mg after 1.0 .mu.g/kg of dexmedetomidine (P = 0.028). Blood pressure, heart rate, and plasma norepinephrine levels were reduced after dexmedetomidine. The optimal dose of dexmedetomidine for single-dose intravenous premedication studies in minor surgery appears to be in the range of 0.33-0.67 .mu.g/kg.